Antibodies to the protein tyrosine phosphatases IAR and IA-2 are associated with progression to insulin-dependent diabetes (IDDM) in first-degree relatives at-risk for IDDM.

Insulin-dependent diabetes mellitus (IDDM) is preceded by the presence of antibodies against islet proteins including a protein tyrosine phosphatase (PTP) designated IA-2. Recently, we cloned a novel PTP named IAR which shares 43% sequence identity with IA-2 and is recognised by antibodies from a majority of patients with IDDM. The aim of the present study was to determine whether IAR antibodies (IAR Ab) or IA-2 antibodies (IA-2 Ab) are associated with progression to IDDM in first-degree relatives "at-risk" for IDDM (operationally defined as those with islet cell antibodies [ICA] > or = 20JDFU or insulin autoantibodies [IAA] > or = 100 nU/ml), and to examine combinations of IAR Ab and IA-2 Ab in these subjects. The sensitivity and specificity of these antibodies were also examined in patients with recent-onset IDDM. Using Cox's Proportional Hazards Model, the number of siblings with IDDM was associated with progression to IDDM in "at-risk" relatives, but other covariables (age, sex, number of affected offspring or parents) were not significantly associated. Using number of affected siblings as a covariable, both IAR and IA-2 antibodies were significantly associated with progression to IDDM (p < 0.005). Combinations of both antibodies, however, did not result in a significantly stronger association with progression to IDDM. The threshold of positivity for IAR Ab (0.5 units) and IA-2 Ab (3.0 units) assays was adjusted to give the same specificity (97.9%) for each assay in 144 healthy control subjects, to allow standardised comparisons. Levels of IAR Ab and IA-2 Ab were strongly correlated in 53 recent-onset IDDM patients (r = 0.70, p < 0.0001) but 11.3% had IAR Ab in the absence of IA-2 Ab and 16.9% had IA-2 Ab in the absence of IAR Ab. The sensitivity for IDDM (defined as the proportion of IDDM patients positive) was 56.6% for IAR Ab and 62.3% for IA-2 Ab. We conclude that there is considerable overlap in IA-2 Ab and IAR Ab positivity, although either antibody can occur independently in IDDM patients. Both IAR Ab and IA-2 antibodies are associated with progression to IDDM in first-degree relatives at-risk of IDDM, but the use of IAR and IA-2 antibodies in combination are not significantly more strongly associated with progression than single antibodies. IAR Ab may play an important role in the prediction of IDDM.

[1]  P. D. Smith,et al.  ICAAR, a novel member of a new family of transmembrane, tyrosine phosphatase-like proteins. , 1996, Biochemical and biophysical research communications.

[2]  G. Eisenbarth,et al.  Molecular cloning and characterization of the human transmembrane protein tyrosine phosphatase homologue, phogrin, an autoantigen of type 1 diabetes. , 1996, Biochemical and biophysical research communications.

[3]  H. Deaizpurua,et al.  Cloning and Characterization of Islet Cell Antigen-related Protein-tyrosine Phosphatase (PTP), a Novel Receptor-like PTP and Autoantigen in Insulin-dependent Diabetes* , 1996, The Journal of Biological Chemistry.

[4]  G. Eisenbarth,et al.  Autoantibodies to Protein Tyrosine Phosphatase-Like Proteins In Type I Diabetes: Overlapping Specificities To Phogrin And ICA512/IA-2 , 1996, Diabetes.

[5]  J. Hutton,et al.  Identification of the 37-kDa Antigen in IDDM as a Tyrosine Phosphatase-Like Protein (Phogrin) Related to IA-2 , 1996, Diabetes.

[6]  J. Hutton,et al.  Molecular Cloning of Phogrin, a Protein-tyrosine Phosphatase Homologue Localized to Insulin Secretory Granule Membranes* , 1996, The Journal of Biological Chemistry.

[7]  J. Flanagan,et al.  PTP-NP, a new member of the receptor protein tyrosine phosphatase family, implicated in development of nervous system and pancreatic endocrine cells. , 1996, Development.

[8]  H. Chase,et al.  Prediction of Type I Diabetes in First-Degree Relatives Using a Combination of Insulin, GAD, and ICA512bdc/IA-2 Autoantibodies , 1996, Diabetes.

[9]  M. Solimena,et al.  ICA 512, an autoantigen of type I diabetes, is an intrinsic membrane protein of neurosecretory granules. , 1996, The EMBO journal.

[10]  M. Lan,et al.  Identification of a second transmembrane protein tyrosine phosphatase, IA-2beta, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[11]  E. Bonifacio,et al.  Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. , 1995, Journal of immunology.

[12]  Roberto Gianani,et al.  ICA512 Autoantibody Radioassay , 1995, Diabetes.

[13]  E. Appella,et al.  The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[14]  M. Christie,et al.  Relationship of the 37,000- and 40,000-M(r) tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). , 1995, The Journal of clinical investigation.

[15]  L. Harrison,et al.  Reproducibility of the First-Phase Insulin Response to Intravenous Glucose Is Not Improved by Retrograde Cannulation and Arterialization or the Use of a Lower Glucose Dose , 1995, Diabetes Care.

[16]  Å. Lernmark,et al.  Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children. , 1995, The Journal of clinical investigation.

[17]  P. Bingley,et al.  Combined Analysis of Autoantibodies Improves Prediction of IDDM in Islet Cell Antibody-Positive Relatives , 1994, Diabetes.

[18]  M. Lan,et al.  Isolation, sequence and expression of a novel mouse brain cDNA, mIA-2, and its relatedness to members of the protein tyrosine phosphatase family. , 1994, Biochemical and biophysical research communications.

[19]  L. Trost,et al.  Adriamycin-induced oxidation of myoglobin. , 1994, Biochemical and biophysical research communications.

[20]  E. Bonifacio,et al.  Antibodies to Islet 37k Antigen, But Not to Glutamate Decarboxylase, Discriminate Rapid Progression to IDDM in Endocrine Autoimmunity , 1994, Diabetes.

[21]  M. Silink,et al.  The Incidence of Childhood IDDM in New South Wales, Australia , 1994, Diabetes Care.

[22]  M. Lan,et al.  Molecular cloning and identification of a receptor-type protein tyrosine phosphatase, IA-2, from human insulinoma. , 1994, DNA and cell biology.

[23]  D. Goldstein,et al.  Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. , 1994, Journal of immunology.

[24]  Å. Lernmark,et al.  Autoantibodies in IDDM Primarily Recognize the 65,000-Mr Rather Than 67,000-Mr Isoform of Glutamic Acid Decarboxylase , 1993, Diabetes.

[25]  P. Bingley,et al.  Can We Really Predict IDDM? , 1993, Diabetes.

[26]  L. Harrison,et al.  Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Harrison,et al.  Islet cell antigens in insulin-dependent diabetes: Pandora's box revisited. , 1992, Immunology today.

[28]  R. Leslie,et al.  Antibodies to GAD and Tryptic Fragments of Islet 64K Antigen as Distinct Markers for Development of IDDM: Studies With Identical Twins , 1992, Diabetes.

[29]  D. Daneman,et al.  Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment , 1990, The Journal of experimental medicine.

[30]  E. Bonifacio,et al.  Quantification of islet-cell antibodies and prediction of insulin-dependent diabetes , 1990, The Lancet.

[31]  A. Ziegler,et al.  Life-Table Analysis of Progression to Diabetes of Anti-Insulin Autoantibody-Positive Relatives of Individuals With Type I Diabetes , 1989, Diabetes.

[32]  G. Eisenbarth,et al.  Competitive Insulin Autoantibody Assay: Prospective Evaluation of Subjects at High Risk for Development of Type I Diabetes Mellitus , 1987, Diabetes.

[33]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .